A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

drug protocol number
S1007
drug sponsor
King Faisal Specialist Hospital and Research Centre
drug study
DOCETAXEL Paclitaxel TAMOXIFEN Letrozole
drug trial site
KFSH & RC-R
drug status
Ongoing
drug phase